Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Mtb-Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans

Voogd L. et al, (2024), Vaccines, 12, 1129 - 1129

Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.

Audran R. et al, (2024), J Infect

Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.

Ongarj J. et al, (2024), Tuberculosis (Edinb), 148

Review of the current TB human infection studies for use in accelerating TB vaccine development: A meeting report.

Balasingam S. et al, (2024), J Infect Dis

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Jackson S. et al, (2024), Lancet Microbe

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Satti I. et al, (2024), The Lancet Infectious Diseases

Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment.

Ma J. et al, (2024), Proc Natl Acad Sci U S A, 121

Revaccination with BCG: does it work?

McShane H., (2024), Lancet Infect Dis

Development and application of the direct mycobacterial growth inhibition assay (MGIA): a systematic review

McShane H. et al, (2024), Frontiers in Immunology

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.

Wajja A. et al, (2024), Lancet Infect Dis

Exploring the ethics of tuberculosis human challenge models.

Rohrig A. et al, (2023), J Med Ethics

Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.

Wajja A. et al, (2023), Lancet Infect Dis

Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2.

Higham HE. et al, (2023), Br J Clin Pharmacol

Improving TB vaccine trial efficiency: A tough nut to crack.

Mcshane H., (2023), J Infect Dis

Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2

Higham H. et al, (2023)

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge.

Stylianou E. et al, (2023), Front Immunol, 14

BCG: Past, Present and Future Direction

Morrison H. and McShane H., (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 171 - 195

Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges.

Morrison H. et al, (2023), Front Immunol, 14

Healthy volunteer symptom profile following research bronchoscopy

Morrison H. et al, (2023), EUROPEAN RESPIRATORY JOURNAL, 62

Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi.

Gordon SB. et al, (2023), Wellcome Open Res, 8

Load More

Include forthcoming?